Symptoms in long-term breast cancer survivors: A cross-sectional study in primary care

Maass, Saskia W. M. C.; Boerman, L. M.; Brandenbarg, Daan; Verhaak, Peter; Maduro, John H.; Bock, Geertruida H. de; Berendsen, Annette J.

doi:10.1016/j.breast.2020.09.013

Cited by 17 publications

(11 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings regarding depressive symptoms (part of psychological QoL) align with the literature indicating that breast cancer survivors have greater mental health problems than cancer-free controls ( 56 , 71 – 73 ). The previous qualitative analysis revealed that all women in this sample reported a difficult time pre-diagnosis ( 74 ).…”

Section: Discussionsupporting

confidence: 87%

“…These findings regarding depressive symptoms (part of psychological QoL) align with the literature indicating that breast cancer survivors have greater mental health problems than cancer-free controls (56,(71)(72)(73). The previous qualitative analysis FIGURE 4 | CogState computerized cognitive ability test score box plots for the benign (breast lump autopsy), no-chemo (treatment for breast cancer), and chemo (treatment for breast cancer) groups.…”

Section: Discussionsupporting

confidence: 80%

See 1 more Smart Citation

Health-Related Quality of Life: Longitudinal Analysis From the Time of Breast Biopsy Into the Post-treatment Period

Boivin¹,

Sikorskii²,

Haan³

et al. 2021

Front. Glob. Womens Health

View full text Add to dashboard Cite

Background: The physical, psychological, social, and spiritual quality of life (QoL) may be affected by breast cancer diagnosis and treatment, with mixed findings for psychological quality of life and cognitive ability performance. The present study aimed to evaluate QoL in women over 1 year from biopsy for a breast abnormality.Methods: Self-reported measures of physical, psychological, social, and spiritual QoL were obtained after biopsy results but prior to treatment initiation (baseline), 4 and 12 months later. CogState computerized neuropsychological screening battery also provided an evaluation of psychological QoL. Three groups of women including those with benign biopsy results, those with malignancy treated with chemotherapy, and those with malignancy not treated with chemotherapy were compared at 4 and 12 months after adjusting for baseline to isolate the effects of treatment. Additional covariates included are age, level of education, and income.Results: Benign biopsy results group included 72 women, whereas malignancy was found in 87 women of whom 33 were treated with chemotherapy and 54 without chemotherapy. At the time of diagnosis, women with cancer had worse psychological and social QoL but better spiritual QoL than those with benign biopsy results. Only CogState monitoring accuracy was worse for women with cancer compared with the controls at the time of biopsy results. After adjusting for QoL at baseline, women treated for cancer had worse physical and social QoL at 4 and 12 months later. Psychological well-being was worse for women with cancer at 4th month but improved at 1 year. No differences in cognition were found at 4 and 12 months when adjusted for baseline cognition and covariates.Discussion: Breast cancer is a traumatic life event for women, affecting psychological and social QoL domains, yet increasing spiritual QoL. Later, cancer treatment worsens physical, psychological, and social QoL compared with those without cancer.Conclusions: These findings suggest that interventions to improve psychological QoL may be especially important at the time of cancer diagnosis, while interventions to improve physical well-being are the most needed during and following cancer treatment. Support to improve social QoL is needed from the time of diagnosis into post-treatment survivorship.

show abstract

Section: Discussionsupporting

confidence: 87%

“…These findings regarding depressive symptoms (part of psychological QoL) align with the literature indicating that breast cancer survivors have greater mental health problems than cancer-free controls (56,(71)(72)(73). The previous qualitative analysis FIGURE 4 | CogState computerized cognitive ability test score box plots for the benign (breast lump autopsy), no-chemo (treatment for breast cancer), and chemo (treatment for breast cancer) groups.…”

Section: Discussionsupporting

confidence: 80%

Health-Related Quality of Life: Longitudinal Analysis From the Time of Breast Biopsy Into the Post-treatment Period

Boivin¹,

Sikorskii²,

Haan³

et al. 2021

Front. Glob. Womens Health

View full text Add to dashboard Cite

show abstract

“…Due to younger diagnosis age, lack of social support, physical changes and clinical symptoms caused by treatment, the depression incidence in breast cancer patients is higher than that of other malignant tumor patients. [ 6 , 7 ] Statistics showed that 32.8% of breast cancer patients had depressive symptoms, and 42% of patients with recurrent breast cancer were diagnosed with depression, leading to increased mortality, worse clinical prognosis and quality of life. [ 8 , 9 ] A meta‐analysis showed that depression increases the overall risk of death in breast cancer patients by 30%, breast cancer‐specific mortality by 29%, and the risk of recurrence by 24%.…”

Section: Introductionmentioning

confidence: 99%

HTR1A Inhibits the Progression of Triple‐Negative Breast Cancer via TGF‐β Canonical and Noncanonical Pathways

et al. 2022

View full text Add to dashboard Cite

Triple‐negative breast cancer is the most aggressive subtype of breast cancer and the incidence of depression in breast cancer patients is high, which leading to worse survival and increased risk of recurrence. The effect of antidepressants on breast cancer patients remains contradictory, which might be due to variations in antidepression targets. Therefore, there is significant value to explore the antitumor potential of antidepressants and discover new therapeutic targets for breast patients. The authors screen antidepressant‐related oncogenes or suppressors by using siRNAs. After combining functional experiments with online database analysis, 5‐hydroxytryptamine receptor 1A (HTR1A is selected with antitumor potential in breast cancer cells in vivo and in vitro. RNA‐seq analysis and coimmunoprecipitation assays indicate that HTR1A interacts with TRIM21 and PSMD7 to inhibit the degradation of T β RII through the ubiquitin‐proteasome pathway, thereby inhibiting the transforming growth factor‐ β (TGF‐β) canonical and noncanonical pathway. In addition, HTR1A is an independent predictive factor for breast cancer patients. The combined treatment of HTR1A agonists with demethylation drugs may significantly improve patient survival. It is of great significance to clarify the function and mechanism of the depression‐related gene HTR1A in breast cancer, which might provide a new approach for triple‐negative breast cancer patients.

show abstract

“…Motor nerve damage can be manifested as weakness, gait and balance disturbance, and difficulties in fine motor skills[ 5 , 6 ]. Furthermore, automatic nerve damage leads to dizziness, blurred vision, constipation, orthostatic hypotension, and erectile dysfunction[ 7 , 8 ]. CIPN can cause persistent pain, loss of fine sensation, and muscle weakness, leading to disability in severe cases[ 4 , 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

Psychosocial adaptation and influencing factors among patients with chemotherapy-induced peripheral neuropathy

Zhou¹,

Wang²,

Ding³

et al. 2022

WJCC

View full text Add to dashboard Cite

BACKGROUND Chemotherapy-induced peripheral neuropathy (CIPN) is a severe and long-lasting side effect caused by various anticancer agents that damage sensory, motor and autonomic nerves. It can cause maladaptive behaviors, including disease severity, anxiety, depression, sleep disorders, falls, and social impairment. These disorders have physical, psychological and social effects on patients and can seriously influence their quality of life. AIM To investigate the current situation of psychosocial adaptation to the disease and its influencing factor in patients with CIPN. METHODS A convenience sampling method was used to select 233 patients with CIPN in our hospital from February to August 2021. In addition, a cross-sectional survey was conducted using a sociodemographic questionnaire, the Self-Report Psychosocial Adjustment to Illness Scale, and the European Organisation for the Research and Treatment of Cancer Quality of Life CIPN20 (QLQ-CIPN20). Factors influencing psychosocial adaptation in patients with CIPN were analyzed by t -test or one-way analysis of variance, correlation analysis, multiple stepwise regression analysis, and structural equation models. RESULTS The psychosocial adaptation score of patients with CIPN was 52.51 ± 13.18. Multivariate analysis showed that autonomic nerves, tumor stage, motor nerves, education level, availability of caregivers, semi-retirement status, CIPN grade were independent risk factors for patients with CIPN ( P < 0.05). Structural equation models showed that QLQ-CIPN20 mediated the relationship between CIPN grade, tumor stage, and psychosocial adaptation. CONCLUSION Patients with CIPN have poor psychosocial adaptation and are affected by a variety of physiological, psychological, and social factors. Patients’ adaptive responses should be assessed, and targeted interventions implemented.

show abstract

Symptoms in long-term breast cancer survivors: A cross-sectional study in primary care

Cited by 17 publications

References 41 publications

Health-Related Quality of Life: Longitudinal Analysis From the Time of Breast Biopsy Into the Post-treatment Period

Health-Related Quality of Life: Longitudinal Analysis From the Time of Breast Biopsy Into the Post-treatment Period

HTR1A Inhibits the Progression of Triple‐Negative Breast Cancer via TGF‐β Canonical and Noncanonical Pathways

Psychosocial adaptation and influencing factors among patients with chemotherapy-induced peripheral neuropathy

Contact Info

Product

Resources

About